APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nano-antibody CDMO Services

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nano-antibody CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025197 pages

Choose your research edition.

Industry ResearchNano-antibody CDMO Services Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Nano-antibody CDMO Services Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Nano-antibody CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nano-antibody CDMO Services Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Nano-antibody CDMO Services Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Nano-antibody CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nano-antibody CDMO Services include Nuoanjian Biotech, BioInno Biotechnology, Sanofi, Medicilon, Bioworkshops, Yaohai Bio, Abace Biotechnology, Shilpa Biologicals Private and ProBio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Nano-antibody CDMO Services market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nano-antibody CDMO Services and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nano-antibody CDMO Services revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Nano-antibody CDMO Services market size, projected growth trends, production technologies, key applications, and end-use industries.

Nano-antibody CDMO Services Segment by Company

Nuoanjian Biotech

BioInno Biotechnology

Sanofi

Medicilon

Bioworkshops

Yaohai Bio

Abace Biotechnology

Shilpa Biologicals Private

ProBio

PolyPeptide

Pierre Fabre

PeptiFinder Biotech

Jotbody

ImmunoPrecise Antibodies

GenScript

Cultiply

CordenPharma

Bachem

Abzena

53Biologics

Nano-antibody CDMO Services Segment by Type

Vector Construction

Antigen Design

Gene Synthesis

Others

Nano-antibody CDMO Services Segment by Application

Pharmaceutical Companies

Biological Laboratories

Others

Nano-antibody CDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano-antibody CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nano-antibody CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano-antibody CDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Nano-antibody CDMO Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nano-antibody CDMO Services industry.

Chapter 3: Detailed analysis of Nano-antibody CDMO Services companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nano-antibody CDMO Servicesrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nano-antibody CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Vector Construction Table 3. Key Players of Antigen Design Table 4. Key Players of Gene Synthesis Table 3. Key Players of Others Table 4. Global Nano-antibody CDMO Services Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Pharmaceutical Companies Table 6. Key Players of Biological Laboratories Table 7. Key Players of Others Table 8. Global Nano-antibody CDMO Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Nano-antibody CDMO Services Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Nano-antibody CDMO Services Market Share by Region (2021-2026) Table 11. Global Nano-antibody CDMO Services Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Nano-antibody CDMO Services Market Share by Region (2027-2032) Table 13. Nano-antibody CDMO Services Industry Trends Table 14. Nano-antibody CDMO Services Industry Drivers Table 15. Nano-antibody CDMO Services Industry Opportunities and Challenges Table 16. Nano-antibody CDMO Services Industry Restraints Table 17. Global Nano-antibody CDMO Services Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Nano-antibody CDMO Services Revenue Market Share by Company (2021-2026) Table 19. Global Nano-antibody CDMO Services Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Nano-antibody CDMO Services Key Company Head Office and Area Served Table 21. Global Nano-antibody CDMO Services Company, Product Type & Application Table 22. Global Nano-antibody CDMO Services Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Nano-antibody CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Nano-antibody CDMO Services Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Nano-antibody CDMO Services Revenue Market Share by Type (2021-2026) Table 29. Global Nano-antibody CDMO Services Revenue Market Share by Type (2027-2032) Table 30. Global Nano-antibody CDMO Services Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Nano-antibody CDMO Services Revenue Market Share by Application (2021-2026) Table 34. Global Nano-antibody CDMO Services Revenue Market Share by Application (2027-2032) Table 35. Nuoanjian Biotech Company Information Table 36. Nuoanjian Biotech Business Overview Table 37. Nuoanjian Biotech Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Nuoanjian Biotech Nano-antibody CDMO Services Product Portfolio Table 39. Nuoanjian Biotech Recent Development Table 40. BioInno Biotechnology Company Information Table 41. BioInno Biotechnology Business Overview Table 42. BioInno Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. BioInno Biotechnology Nano-antibody CDMO Services Product Portfolio Table 44. BioInno Biotechnology Recent Development Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Sanofi Nano-antibody CDMO Services Product Portfolio Table 49. Sanofi Recent Development Table 50. Medicilon Company Information Table 51. Medicilon Business Overview Table 52. Medicilon Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Medicilon Nano-antibody CDMO Services Product Portfolio Table 54. Medicilon Recent Development Table 55. Bioworkshops Company Information Table 56. Bioworkshops Business Overview Table 57. Bioworkshops Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bioworkshops Nano-antibody CDMO Services Product Portfolio Table 59. Bioworkshops Recent Development Table 60. Yaohai Bio Company Information Table 61. Yaohai Bio Business Overview Table 62. Yaohai Bio Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Yaohai Bio Nano-antibody CDMO Services Product Portfolio Table 64. Yaohai Bio Recent Development Table 65. Abace Biotechnology Company Information Table 66. Abace Biotechnology Business Overview Table 67. Abace Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Abace Biotechnology Nano-antibody CDMO Services Product Portfolio Table 69. Abace Biotechnology Recent Development Table 70. Shilpa Biologicals Private Company Information Table 71. Shilpa Biologicals Private Business Overview Table 72. Shilpa Biologicals Private Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Shilpa Biologicals Private Nano-antibody CDMO Services Product Portfolio Table 74. Shilpa Biologicals Private Recent Development Table 75. ProBio Company Information Table 76. ProBio Business Overview Table 77. ProBio Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. ProBio Nano-antibody CDMO Services Product Portfolio Table 79. ProBio Recent Development Table 80. PolyPeptide Company Information Table 81. PolyPeptide Business Overview Table 82. PolyPeptide Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. PolyPeptide Nano-antibody CDMO Services Product Portfolio Table 84. PolyPeptide Recent Development Table 85. Pierre Fabre Company Information Table 86. Pierre Fabre Business Overview Table 87. Pierre Fabre Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Pierre Fabre Nano-antibody CDMO Services Product Portfolio Table 89. Pierre Fabre Recent Development Table 90. PeptiFinder Biotech Company Information Table 91. PeptiFinder Biotech Business Overview Table 92. PeptiFinder Biotech Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. PeptiFinder Biotech Nano-antibody CDMO Services Product Portfolio Table 94. PeptiFinder Biotech Recent Development Table 95. Jotbody Company Information Table 96. Jotbody Business Overview Table 97. Jotbody Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Jotbody Nano-antibody CDMO Services Product Portfolio Table 99. Jotbody Recent Development Table 100. ImmunoPrecise Antibodies Company Information Table 101. ImmunoPrecise Antibodies Business Overview Table 102. ImmunoPrecise Antibodies Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Portfolio Table 104. ImmunoPrecise Antibodies Recent Development Table 105. GenScript Company Information Table 106. GenScript Business Overview Table 107. GenScript Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. GenScript Nano-antibody CDMO Services Product Portfolio Table 109. GenScript Recent Development Table 110. Cultiply Company Information Table 111. Cultiply Business Overview Table 112. Cultiply Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. Cultiply Nano-antibody CDMO Services Product Portfolio Table 114. Cultiply Recent Development Table 115. CordenPharma Company Information Table 116. CordenPharma Business Overview Table 117. CordenPharma Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 118. CordenPharma Nano-antibody CDMO Services Product Portfolio Table 119. CordenPharma Recent Development Table 120. Bachem Company Information Table 121. Bachem Business Overview Table 122. Bachem Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 123. Bachem Nano-antibody CDMO Services Product Portfolio Table 124. Bachem Recent Development Table 125. Abzena Company Information Table 126. Abzena Business Overview Table 127. Abzena Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 128. Abzena Nano-antibody CDMO Services Product Portfolio Table 129. Abzena Recent Development Table 130. 53Biologics Company Information Table 131. 53Biologics Business Overview Table 132. 53Biologics Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 133. 53Biologics Nano-antibody CDMO Services Product Portfolio Table 134. 53Biologics Recent Development Table 135. North America Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 136. North America Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 137. North America Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 138. North America Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 139. North America Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Nano-antibody CDMO Services Market Size by Country (2021-2026) Table 141. North America Nano-antibody CDMO Services Market Size by Country (2027-2032) Table 142. Europe Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 143. Europe Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 144. Europe Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 145. Europe Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 146. Europe Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Nano-antibody CDMO Services Market Size by Country (2021-2026) Table 148. Europe Nano-antibody CDMO Services Market Size by Country (2027-2032) Table 149. China Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 150. China Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 151. China Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 152. China Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 153. Asia Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 154. Asia Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 155. Asia Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 156. Asia Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 157. Asia Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Nano-antibody CDMO Services Market Size by Country (2021-2026) Table 159. Asia Nano-antibody CDMO Services Market Size by Country (2027-2032) Table 160. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 161. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Type (2027-2032) & (US$ Million) Table 162. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 163. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Application (2027-2032) & (US$ Million) Table 164. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2021-2026) Table 166. South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Nano-antibody CDMO Services Product Image Figure 2. Global Nano-antibody CDMO Services Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Nano-antibody CDMO Services Market Share by Type: 2025 VS 2032 Figure 4. Vector Construction Image Figure 5. Antigen Design Image Figure 6. Gene Synthesis Image Figure 7. Others Image Figure 8. Global Nano-antibody CDMO Services Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Nano-antibody CDMO Services Market Share by Application: 2025 VS 2032 Figure 10. Pharmaceutical Companies Image Figure 11. Biological Laboratories Image Figure 12. Others Image Figure 13. Global Nano-antibody CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 15. Global Nano-antibody CDMO Services Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global Nano-antibody CDMO Services Market Share by Players in 2025 Figure 18. Global Top 5 and 10 Nano-antibody CDMO Services Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Nano-antibody CDMO Services Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Nano-antibody CDMO Services Revenue Market Share by Type (2021-2032) Figure 22. Global Nano-antibody CDMO Services Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nano-antibody CDMO Services Revenue Market Share by Application (2021-2032) Figure 24. North America Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 25. North America Nano-antibody CDMO Services Market Share by Type (2021-2032) Figure 26. North America Nano-antibody CDMO Services Market Share by Application (2021-2032) Figure 27. North America Nano-antibody CDMO Services Market Share by Country (2021-2032) Figure 28. United States Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 29. Canada Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 30. Mexico Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 31. Europe Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 32. Europe Nano-antibody CDMO Services Market Share by Type (2021-2032) Figure 33. Europe Nano-antibody CDMO Services Market Share by Application (2021-2032) Figure 34. Europe Nano-antibody CDMO Services Market Share by Country (2021-2032) Figure 35. Germany Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 36. France Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 37. U.K. Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 38. Italy Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 39. Russia Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 41. China Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 42. China Nano-antibody CDMO Services Market Share by Type (2021-2032) Figure 43. China Nano-antibody CDMO Services Market Share by Application (2021-2032) Figure 44. Asia Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 45. Asia Nano-antibody CDMO Services Market Share by Type (2021-2032) Figure 46. Asia Nano-antibody CDMO Services Market Share by Application (2021-2032) Figure 47. Asia Nano-antibody CDMO Services Market Share by Country (2021-2032) Figure 48. Japan Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 49. South Korea Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 52. India Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 53. Australia Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Country (2021-2032) Figure 58. Brazil Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 59. South Africa Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 61. Turkey Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 62. Argentina Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 63. UAE Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 64. Egypt Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 65. Chile Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Vector Construction
  • Antigen Design
  • Gene Synthesis
  • Others
Applications
  • Pharmaceutical Companies
  • Biological Laboratories
  • Others
Companies covered
  • Nuoanjian Biotech
  • BioInno Biotechnology
  • Sanofi
  • Medicilon
  • Bioworkshops
  • Yaohai Bio
  • Abace Biotechnology
  • Shilpa Biologicals Private
  • ProBio
  • PolyPeptide
  • Pierre Fabre
  • PeptiFinder Biotech
  • Jotbody
  • ImmunoPrecise Antibodies
  • GenScript
  • Cultiply
  • CordenPharma
  • Bachem
  • Abzena
  • 53Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Nano-antibody CDMO Services Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Vector Construction
  5. 1.2.3 Antigen Design
  6. 1.2.4 Gene Synthesis
  7. 1.2.5 Others
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Nano-antibody CDMO Services Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical Companies
  11. 1.3.3 Biological Laboratories
  12. 1.3.4 Others
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global Nano-antibody CDMO Services Growth Trends by Region
  15. 1.5.1 Global Nano-antibody CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 Nano-antibody CDMO Services Market Size by Region (2021-2026)
  17. 1.5.3 Nano-antibody CDMO Services Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global Nano-antibody CDMO Services Market Dynamics
  1. 2.1 Nano-antibody CDMO Services Industry Trends
  2. 2.2 Nano-antibody CDMO Services Industry Drivers
  3. 2.3 Nano-antibody CDMO Services Industry Opportunities and Challenges
  4. 2.4 Nano-antibody CDMO Services Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Nano-antibody CDMO Services Revenue by Company (2021-2026)
  2. 3.2 Global Nano-antibody CDMO Services Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Nano-antibody CDMO Services Key Company Head office and Area Served
  4. 3.4 Global Nano-antibody CDMO Services Company, Product Type & Application
  5. 3.5 Global Nano-antibody CDMO Services Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Nano-antibody CDMO Services Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Nano-antibody CDMO Services Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Nano-antibody CDMO Services Tier 1, Tier 2, and Tier 3
4 Nano-antibody CDMO Services Market by Type
  1. 4.1 Global Nano-antibody CDMO Services Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Nano-antibody CDMO Services Market Size by Type (2021-2032)
  3. 4.3 Global Nano-antibody CDMO Services Market Size Share by Type (2021-2032)
5 Nano-antibody CDMO Services Market by Application
  1. 5.1 Global Nano-antibody CDMO Services Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Nano-antibody CDMO Services Market Size by Application (2021-2032)
  3. 5.3 Global Nano-antibody CDMO Services Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Nuoanjian Biotech
  2. 6.1.1 Nuoanjian Biotech Company Information
  3. 6.1.2 Nuoanjian Biotech Business Overview
  4. 6.1.3 Nuoanjian Biotech Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Nuoanjian Biotech Nano-antibody CDMO Services Product Portfolio
  6. 6.1.5 Nuoanjian Biotech Recent Developments
  7. 6.2 BioInno Biotechnology
  8. 6.2.1 BioInno Biotechnology Company Information
  9. 6.2.2 BioInno Biotechnology Business Overview
  10. 6.2.3 BioInno Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 BioInno Biotechnology Nano-antibody CDMO Services Product Portfolio
  12. 6.2.5 BioInno Biotechnology Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Sanofi Nano-antibody CDMO Services Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Medicilon
  20. 6.4.1 Medicilon Company Information
  21. 6.4.2 Medicilon Business Overview
  22. 6.4.3 Medicilon Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Medicilon Nano-antibody CDMO Services Product Portfolio
  24. 6.4.5 Medicilon Recent Developments
  25. 6.5 Bioworkshops
  26. 6.5.1 Bioworkshops Company Information
  27. 6.5.2 Bioworkshops Business Overview
  28. 6.5.3 Bioworkshops Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bioworkshops Nano-antibody CDMO Services Product Portfolio
  30. 6.5.5 Bioworkshops Recent Developments
  31. 6.6 Yaohai Bio
  32. 6.6.1 Yaohai Bio Company Information
  33. 6.6.2 Yaohai Bio Business Overview
  34. 6.6.3 Yaohai Bio Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Yaohai Bio Nano-antibody CDMO Services Product Portfolio
  36. 6.6.5 Yaohai Bio Recent Developments
  37. 6.7 Abace Biotechnology
  38. 6.7.1 Abace Biotechnology Company Information
  39. 6.7.2 Abace Biotechnology Business Overview
  40. 6.7.3 Abace Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Abace Biotechnology Nano-antibody CDMO Services Product Portfolio
  42. 6.7.5 Abace Biotechnology Recent Developments
  43. 6.8 Shilpa Biologicals Private
  44. 6.8.1 Shilpa Biologicals Private Company Information
  45. 6.8.2 Shilpa Biologicals Private Business Overview
  46. 6.8.3 Shilpa Biologicals Private Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Shilpa Biologicals Private Nano-antibody CDMO Services Product Portfolio
  48. 6.8.5 Shilpa Biologicals Private Recent Developments
  49. 6.9 ProBio
  50. 6.9.1 ProBio Company Information
  51. 6.9.2 ProBio Business Overview
  52. 6.9.3 ProBio Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 ProBio Nano-antibody CDMO Services Product Portfolio
  54. 6.9.5 ProBio Recent Developments
  55. 6.10 PolyPeptide
  56. 6.10.1 PolyPeptide Company Information
  57. 6.10.2 PolyPeptide Business Overview
  58. 6.10.3 PolyPeptide Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 PolyPeptide Nano-antibody CDMO Services Product Portfolio
  60. 6.10.5 PolyPeptide Recent Developments
  61. 6.11 Pierre Fabre
  62. 6.11.1 Pierre Fabre Company Information
  63. 6.11.2 Pierre Fabre Business Overview
  64. 6.11.3 Pierre Fabre Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Pierre Fabre Nano-antibody CDMO Services Product Portfolio
  66. 6.11.5 Pierre Fabre Recent Developments
  67. 6.12 PeptiFinder Biotech
  68. 6.12.1 PeptiFinder Biotech Company Information
  69. 6.12.2 PeptiFinder Biotech Business Overview
  70. 6.12.3 PeptiFinder Biotech Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 PeptiFinder Biotech Nano-antibody CDMO Services Product Portfolio
  72. 6.12.5 PeptiFinder Biotech Recent Developments
  73. 6.13 Jotbody
  74. 6.13.1 Jotbody Company Information
  75. 6.13.2 Jotbody Business Overview
  76. 6.13.3 Jotbody Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Jotbody Nano-antibody CDMO Services Product Portfolio
  78. 6.13.5 Jotbody Recent Developments
  79. 6.14 ImmunoPrecise Antibodies
  80. 6.14.1 ImmunoPrecise Antibodies Company Information
  81. 6.14.2 ImmunoPrecise Antibodies Business Overview
  82. 6.14.3 ImmunoPrecise Antibodies Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Portfolio
  84. 6.14.5 ImmunoPrecise Antibodies Recent Developments
  85. 6.15 GenScript
  86. 6.15.1 GenScript Company Information
  87. 6.15.2 GenScript Business Overview
  88. 6.15.3 GenScript Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 GenScript Nano-antibody CDMO Services Product Portfolio
  90. 6.15.5 GenScript Recent Developments
  91. 6.16 Cultiply
  92. 6.16.1 Cultiply Company Information
  93. 6.16.2 Cultiply Business Overview
  94. 6.16.3 Cultiply Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Cultiply Nano-antibody CDMO Services Product Portfolio
  96. 6.16.5 Cultiply Recent Developments
  97. 6.17 CordenPharma
  98. 6.17.1 CordenPharma Company Information
  99. 6.17.2 CordenPharma Business Overview
  100. 6.17.3 CordenPharma Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 CordenPharma Nano-antibody CDMO Services Product Portfolio
  102. 6.17.5 CordenPharma Recent Developments
  103. 6.18 Bachem
  104. 6.18.1 Bachem Company Information
  105. 6.18.2 Bachem Business Overview
  106. 6.18.3 Bachem Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Bachem Nano-antibody CDMO Services Product Portfolio
  108. 6.18.5 Bachem Recent Developments
  109. 6.19 Abzena
  110. 6.19.1 Abzena Company Information
  111. 6.19.2 Abzena Business Overview
  112. 6.19.3 Abzena Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Abzena Nano-antibody CDMO Services Product Portfolio
  114. 6.19.5 Abzena Recent Developments
  115. 6.20 53Biologics
  116. 6.20.1 53Biologics Company Information
  117. 6.20.2 53Biologics Business Overview
  118. 6.20.3 53Biologics Nano-antibody CDMO Services Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 53Biologics Nano-antibody CDMO Services Product Portfolio
  120. 6.20.5 53Biologics Recent Developments
7 North America
  1. 7.1 North America Nano-antibody CDMO Services Market Size (2021-2032)
  2. 7.2 North America Nano-antibody CDMO Services Market Size by Type
  3. 7.2.1 North America Nano-antibody CDMO Services Market Size by Type (2021-2026)
  4. 7.2.2 North America Nano-antibody CDMO Services Market Size by Type (2027-2032)
  5. 7.2.3 North America Nano-antibody CDMO Services Market Share by Type (2021-2032)
  6. 7.3 North America Nano-antibody CDMO Services Market Size by Application
  7. 7.3.1 North America Nano-antibody CDMO Services Market Size by Application (2021-2026)
  8. 7.3.2 North America Nano-antibody CDMO Services Market Size by Application (2027-2032)
  9. 7.3.3 North America Nano-antibody CDMO Services Market Share by Application (2021-2032)
  10. 7.4 North America Nano-antibody CDMO Services Market Size by Country
  11. 7.4.1 North America Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Nano-antibody CDMO Services Market Size by Country (2021-2026)
  13. 7.4.3 North America Nano-antibody CDMO Services Market Size by Country (2027-2032)
  14. 7.4.4 North America Nano-antibody CDMO Services Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Nano-antibody CDMO Services Market Size (2021-2032)
  2. 8.2 Europe Nano-antibody CDMO Services Market Size by Type
  3. 8.2.1 Europe Nano-antibody CDMO Services Market Size by Type (2021-2026)
  4. 8.2.2 Europe Nano-antibody CDMO Services Market Size by Type (2027-2032)
  5. 8.2.3 Europe Nano-antibody CDMO Services Market Share by Type (2021-2032)
  6. 8.3 Europe Nano-antibody CDMO Services Market Size by Application
  7. 8.3.1 Europe Nano-antibody CDMO Services Market Size by Application (2021-2026)
  8. 8.3.2 Europe Nano-antibody CDMO Services Market Size by Application (2027-2032)
  9. 8.3.3 Europe Nano-antibody CDMO Services Market Share by Application (2021-2032)
  10. 8.4 Europe Nano-antibody CDMO Services Market Size by Country
  11. 8.4.1 Europe Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Nano-antibody CDMO Services Market Size by Country (2021-2026)
  13. 8.4.3 Europe Nano-antibody CDMO Services Market Size by Country (2027-2032)
  14. 8.4.4 Europe Nano-antibody CDMO Services Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Nano-antibody CDMO Services Market Size (2021-2032)
  2. 9.2 China Nano-antibody CDMO Services Market Size by Type
  3. 9.2.1 China Nano-antibody CDMO Services Market Size by Type (2021-2026)
  4. 9.2.2 China Nano-antibody CDMO Services Market Size by Type (2027-2032)
  5. 9.2.3 China Nano-antibody CDMO Services Market Share by Type (2021-2032)
  6. 9.3 China Nano-antibody CDMO Services Market Size by Application
  7. 9.3.1 China Nano-antibody CDMO Services Market Size by Application (2021-2026)
  8. 9.3.2 China Nano-antibody CDMO Services Market Size by Application (2027-2032)
  9. 9.3.3 China Nano-antibody CDMO Services Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Nano-antibody CDMO Services Market Size (2021-2032)
  2. 10.2 Asia Nano-antibody CDMO Services Market Size by Type
  3. 10.2.1 Asia Nano-antibody CDMO Services Market Size by Type (2021-2026)
  4. 10.2.2 Asia Nano-antibody CDMO Services Market Size by Type (2027-2032)
  5. 10.2.3 Asia Nano-antibody CDMO Services Market Share by Type (2021-2032)
  6. 10.3 Asia Nano-antibody CDMO Services Market Size by Application
  7. 10.3.1 Asia Nano-antibody CDMO Services Market Size by Application (2021-2026)
  8. 10.3.2 Asia Nano-antibody CDMO Services Market Size by Application (2027-2032)
  9. 10.3.3 Asia Nano-antibody CDMO Services Market Share by Application (2021-2032)
  10. 10.4 Asia Nano-antibody CDMO Services Market Size by Country
  11. 10.4.1 Asia Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Nano-antibody CDMO Services Market Size by Country (2021-2026)
  13. 10.4.3 Asia Nano-antibody CDMO Services Market Size by Country (2027-2032)
  14. 10.4.4 Asia Nano-antibody CDMO Services Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Nano-antibody CDMO Services Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Nano-antibody CDMO Services Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Nano-antibody CDMO Services Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst